Related Experiment Videos
Zidovudine inhibits hepatitis B virus replication
L Berk1, S W Schalm, R A Heijtink
1Department of Internal Medicine II, University Hospital Dijkzigt, Rotterdam, The Netherlands.
Antiviral Research
|August 1, 1992
Summary
Zidovudine effectively inhibits hepatitis B virus DNA polymerase activity in vitro and reduces viral replication in patients with chronic hepatitis B. This antiviral may benefit non-responders to interferon therapy.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis B virus (HBV) DNA polymerase is crucial for viral replication, utilizing both DNA and RNA templates.
- Blocking HBV DNA polymerase activity is a potential strategy to reduce viral load.
Purpose of the Study:
- To investigate the in vitro efficacy of zidovudine triphosphate against HBV DNA polymerase.
- To evaluate the in vivo effect of zidovudine on viral replication in patients with chronic hepatitis B.
Main Methods:
- In vitro enzyme assays were performed using zidovudine triphosphate.
- Clinical study involved patients with chronic hepatitis B receiving oral zidovudine at varying doses and durations.
Main Results:
- Zidovudine triphosphate demonstrated significant inhibition of HBV DNA polymerase in vitro (IC50 = 0.3 microM).
- Oral administration of zidovudine led to a significant reduction in serum DNA polymerase activity in treated patients.
- A dose-response relationship was suggested, with higher doses potentially yielding greater reductions in viral activity.
Conclusions:
- Zidovudine exhibits potent antiviral activity against HBV DNA polymerase.
- Zidovudine may serve as a valuable therapeutic option for patients with chronic hepatitis B who do not respond to alpha-interferon or have high viral loads.